SCHEMBL13141708

SCHEMBL13141708

CC(=O)N1CCN(c2ncccc2-c2cc(-c3cccc(F)c3)n[nH]2)CC1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 3/20 0.50
▸ ALOX15 P16050 3/20 0.50
▸ SMN1; SMN2 Q16637 3/20 0.50
▸ NFKB1 P19838 2/20 0.50
▸ NFKB2 Q00653 2/20 0.50
▸ RELA Q04206 2/20 0.50
▸ LMNA P02545 1/20 0.50
▸ TP53 P04637 1/20 0.50
▸ ALOX12 P18054 1/20 0.50
▸ MAPK1 P28482 1/20 0.50
▸ NPSR1 Q6W5P4 2/20 0.47
▸ MEN1 O00255 1/20 0.47
▸ NPC1 O15118 1/20 0.47
▸ CASP1 P29466 1/20 0.47
▸ CASP3 P42574 1/20 0.47
▸ RAB9A P51151 1/20 0.47
▸ KMT2A Q03164 1/20 0.47
▸ SENP8 Q96LD8 1/20 0.47
▸ SENP7 Q9BQF6 1/20 0.47
▸ SENP6 Q9GZR1 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13141699 0.90 TACR3 (0.49) MAPTALOX15SMN1; SMN2NFKB1NFKB2
SCHEMBL13893152 0.88 MAPT (0.47) MAPTALOX15SMN1; SMN2NFKB1NFKB2
SCHEMBL13141793 0.87 MAPT (0.48) MAPTALOX15SMN1; SMN2NFKB1NFKB2
SCHEMBL13141680 0.84 ALOX15 (0.54) MAPTALOX15SMN1; SMN2NFKB1NFKB2
SCHEMBL13141675 0.83 KDM4E (0.48) MAPTALOX15SMN1; SMN2NFKB1NFKB2
SCHEMBL13141682 0.82 MAPT (0.51) MAPTALOX15SMN1; SMN2NFKB1NFKB2
SCHEMBL13141673 0.81 MAPT (0.46) MAPTALOX15SMN1; SMN2NFKB1NFKB2
SCHEMBL3086423 0.79 MAPT (0.47) MAPTALOX15SMN1; SMN2NFKB1NFKB2
SCHEMBL13141670 0.77 CCNT1 (0.43) MAPTALOX15SMN1; SMN2NFKB1NFKB2
SCHEMBL13141668 0.76 HTR6 (0.46) MAPTALOX15SMN1; SMN2NFKB1NFKB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100227845-A1 SUBSTITUTED 1,2,4-OXADIAZOLES AND ANALOGS THEREOF AS CB2 RECEPTOR MODULATORS, USEFUL IN THE TREATMENT OF PAIN, RESPIRATORY AND NON-RESPIRATORY DISEASES WU ZHICAI 2010-09-09 — — US disclosed
US-20100227845-A1 SUBSTITUTED 1,2,4-OXADIAZOLES AND ANALOGS THEREOF AS CB2 RECEPTOR MODULATORS, USEFUL IN THE TREATMENT OF PAIN, RESPIRATORY AND NON-RESPIRATORY DISEASES WU ZHICAI 2010-09-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100227845-A1 SUBSTITUTED 1,2,4-OXADIAZOLES AND ANALOGS THEREOF AS CB2 RECEPTOR MODULATORS, USEFUL IN THE TREATMENT OF PAIN, RESPIRATORY AND NON-RESPIRATORY DISEASES CNR2, CNR1, TRPV1 MAPT 4681/4885ALOX15 597/4885SMN1; SMN2 2684/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback